NCT06974110 2026-04-15
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Recruiting
Clinical Trials
22 trialsNCT07062055 2026-04-01
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT05978193 2026-01-22
SCR-ESCC-01
Shanghai Chest Hospital
Phase 2 Recruiting
NCT04821778 2026-01-21
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT04821843 2026-01-21
Neoadjuvant Treatment Modalities in Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT06676449 2026-01-07
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
Fudan University
Phase 3 Recruiting
NCT07305428 2025-12-26
Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study
The University of Hong Kong
Phase NA Recruiting
NCT07154082 2025-09-04
Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
Tongji Hospital
Phase 2 Recruiting
NCT04958720 2025-07-03
AGAMENON
Fundación Sociedad Española de Oncologia Médica
Recruiting
NCT06356584 2025-06-26
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT06130826 2025-05-30
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT06907602 2025-04-02
ONTRESCC
Peking Union Medical College Hospital
Phase 2/3 Recruiting
NCT06849193 2025-02-27
BTCICTY-001
Zhongda Hospital
Recruiting
NCT05462496 2024-10-15
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT06359275 2024-06-25
PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
Fudan University
Phase 2 Recruiting
NCT06084897 2024-06-14
Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06449937 2024-06-10
Local Liver Treatment for Multi-organ Colorectal Cancer Metastases
Anhui Provincial Hospital
Phase NA Recruiting
NCT04638751 2024-04-05
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
Persephone Biosciences
Recruiting
NCT06173986 2023-12-18
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Shanghai Chest Hospital
Phase 1/2 Recruiting
NCT05202314 2023-02-21
NACSOC-02
Beijing Chao Yang Hospital
Phase NA Recruiting
NCT04688801 2022-11-16
Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
The Second Hospital of Shandong University
Phase NA Recruiting
NCT05507411 2022-08-19
WATCHER
Zhejiang Cancer Hospital
Phase 2 Recruiting